盟科药业(688373) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 33,216,965.04, representing a year-on-year increase of 0.61% compared to CNY 33,016,131.56 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 61,632,475.69, an improvement from a loss of CNY 102,136,623.67 in the previous year[4] - The net cash flow from operating activities was a negative CNY 52,048,195.23, which is an improvement of CNY 48,684,600 compared to the previous year's negative cash flow[8] - Total operating revenue for Q1 2025 was ¥33,216,965.04, a slight increase of 0.61% compared to ¥33,016,131.56 in Q1 2024[18] - Net profit for Q1 2025 was -¥61,632,475.69, an improvement from -¥102,136,623.67 in Q1 2024, indicating a reduction in losses by about 39.7%[19] - The company reported a total comprehensive loss of -¥62,448,515.28 for Q1 2025, an improvement from -¥101,462,981.24 in Q1 2024, reflecting a reduction in overall losses by approximately 38.4%[19] Research and Development - Total R&D expenditure amounted to CNY 53,852,131.73, a decrease of 36.38% from CNY 84,646,910.43 in the same period last year[5] - The ratio of R&D expenditure to operating revenue was 162.12%, down by 94.26 percentage points from 256.38% in the previous year[5] - Research and development expenses for Q1 2025 were ¥53,852,131.73, down from ¥84,646,910.43 in Q1 2024, a decrease of about 36.4%[18] Assets and Liabilities - The total assets at the end of the reporting period were CNY 853,583,427.97, reflecting a slight increase of 0.52% from CNY 849,128,659.62 at the end of the previous year[5] - Total liabilities increased to CNY 469,262,891.34 from CNY 410,164,907.91, representing a significant rise of approximately 14.36%[15] - The company's total equity attributable to shareholders decreased to CNY 384,320,536.63 from CNY 438,963,751.71, a decline of about 12.41%[15] - The total current assets of Shanghai Mengke Pharmaceutical Co., Ltd. amounted to CNY 757,668,471.24, an increase from CNY 748,661,957.20 as of December 31, 2024, reflecting a growth of approximately 1.35%[14] - The company's fixed assets decreased to CNY 5,277,875.94 from CNY 5,824,313.36, a decline of approximately 9.39%[14] - The total non-current liabilities rose to CNY 226,146,768.60 from CNY 197,868,324.69, reflecting an increase of about 14.26%[15] Shareholder Information - The company had a total of 12,645 ordinary shareholders at the end of the reporting period[11] - The basic and diluted earnings per share were both CNY -0.09, an improvement from CNY -0.16 in the same period last year[4] - Cash and cash equivalents at the end of Q1 2025 increased to ¥322,037,559.34 from ¥216,661,647.43 at the end of Q1 2024, marking a growth of approximately 48.7%[21] Cash Flow - Cash inflow from investment activities for Q1 2025 was ¥856,791,336.86, compared to ¥646,070,755.08 in Q1 2024, indicating an increase of about 32.5%[21] - Cash flow from financing activities for Q1 2025 was ¥56,951,672.67, significantly higher than ¥23,057,563.95 in Q1 2024, representing an increase of approximately 147.5%[21]